News - Dermatologicals, North America


Popular Filters

1 to 25 of 27 results

US FDA clears Xolair for chronic idiopathic urticaria


Swiss drug major Novartis says the US Food and Drug Administration has approved Xolair (omalizumab) for…

BiotechnologyDermatologicalsGenentechNorth AmericaNovartisRegulationRocheUSAXolair

US FDA approves Pierre Fabre’s Hemangeol for infantile hemangioma

US FDA approves Pierre Fabre’s Hemangeol for infantile hemangioma


Pierre Fabre Dermatologie has obtained marketing authorization from the US Food and Drug Administration…

DermatologicalsHemangeolNorth AmericaPharmaceuticalPierre FabreRegulationUSA

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer

KYTHERA regains rights to ATX-101 outside USA and Canada from Bayer


US biotech firm KYTHERA Biopharmaceuticals says it has re-acquired all rights outside of the USA and…

ATX-101BayerDermatologicalsKYTHERA BiopharmaceuticalsLicensingNorth AmericaPharmaceutical

Everett Labs acquires Quinnova Pharma to diversify US market presence


US specialty pharma firm Everett Laboratories, a subsidiary of Spain’s Exeltis, has acquired Quinnova…

Amneal EnterprisesDermatologicalsEverett LaboratoriesExeltisMergers & AcquisitionsNorth AmericaPharmaceuticalQuinnova PharmaceuticalsUSAWomen's Health

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib


Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the…

DermatologicalsNorth AmericaPfizerPharmaceuticalResearchtofacitinibXeljanz

ICAAC: Positive preliminary results of new luliconazole formulation in onychymycosis trial


Luliconazole, a medication approved in Japan for the treatment of superficial mycosis in a 1% formulation,…

DermatologicalsLuliconazoleNihon NohyakuNorth AmericaPharmaceuticalResearch

Galderma drug is first FDA-approved facial erythema of rosacea treatment


Switzerland-headquartered Galderma Laboratories says that the US Food and Drug Administration has approved…

brimonidineDermatologicalsGaldermaMirvasoNorth AmericaPharmaceuticalRegulation

Actelion bid for Ceptaris looks secured as FDA approves Valchlor


Privately-held USA-based Ceptaris Therapeutics revealed yesterday (August 26) that the US Food and Drug…

ActelionBiotechnologyCeptaris TherapeuticsDermatologicalsMergers & AcquisitionsNorth AmericaRegulationValchlor

Galen in upfront $4.5million deal with Novo Research for US rights for Synera pain relief patch


Canada's Nuvo Research (TSX: NRI) today (July 11) announced that its wholly owned subsidiary, ZARS Pharma,…

DermatologicalsGalen USLicensingNorth AmericaNuvo ResearchPharmaceuticalSyneraZARS Pharma

Sales of psoriasis drugs to be worth $7.4 billion by 2020


The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

News briefs: Dr Reddy's launches generic Accutane; Cyprus drug shortages


Indian drugmaker Dr Reddy's Laboratories (NYSE: RDY) says it launched Zenatane (isotretinoin capsules…

AccutaneDermatologicalsDr Reddy's LaboratoriesEuropeGenericsHealthcareMarkets & MarketingNorth AmericaPharmaceuticalZenatane

Briefs: Glenmark challenges Bayer patent; FDA delays Merck & Co's sugammadex


Indian drugmaker Glenmark Generics confirms that it seeking US Food and Drug Administration approval…

BayerBridionDermatologicalsFinacea GelGenericsGlenmark PharmaceuticalsMerck & CoNeurologicalNorth AmericaPatentsPharmaceuticalRegulationsugammadex

Shire settles with Impax on Adderall XR authorized generic; initiates Ph III ABH001 study


Ireland-based drugmaker Shire (LSE: SHP) says it has settled all pending litigation with Impax Laboratories…

ABH001Adderall XRDermatologicalsGenericsImpax LaboratoriesLegalNeurologicalNorth AmericaPharmaceuticalResearchShire

Ranbaxy Labs' Absorica debuts in USA


Indian drugmaker Ranbaxy Laboratories (AB: BO), which is majority owned by Japan's Daiichi Sankyo, said…

AbsoricaCipher PharmaceuticalsDaiichi SankyoDermatologicalsGalephar Pharmaceutival ResearchGenericsMarkets & MarketingNorth AmericaPharmaceuticalRanbaxy Laboratories

Shire's Dermagraft cleared in Canada; settles Intuniv litigation


Ireland headquartered Shire (LSE: SHP), NASDAQ: SHPG) says that its lead regenerative medicine product,…

Anchen PharmaceuticalsDermagraftDermatologicalsDiabetesGenericsIntunivNeurologicalNorth AmericaPatentsPharmaceuticalRegulationShireTWi Pharmaceuticals

Watson confirms patent challenges for Xopenox HFA and Epiduo Gel


US generics drugmaker Watson Pharmaceuticals NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories…

Dainippon Sumitomo PharmaDermatologicalsEpiduo GelGaldermaGenericsLegalNorth AmericaRegulationRespiratory and PulmonarySunovionWatson PharmaceuticalsXopenox

US FTC puts conditions on Novartis buy of Fougera


The USA's Federal Trade Commission said yesterday that it will require Swiss drug major drug Novartis…

DermatologicalsFougera PharmaceuticalsGenericsMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalTolmar

Janssen files NDA with FDA for canagliflozin in type 2 diabetes


Janssen Research & Development, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ) has submitted…

canagliflozinDermatologicalsJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Ranbaxy gains US FDA approval for Absorica


India's largest drugmaker Ranbaxy Laboratories (AB: BO) has received approval from the US Food and Drug…

AbsoricaCipher PharmaceuticalsDermatologicalsIsotretinoinNorth AmericaPharmaceuticalRanbaxy LaboratoriesRegulation

LEO Pharma gets FDA nod for Picato


Independent Danish drugmaker LEO Pharma says that the US Food and Drug Administration has approved its…

DermatologicalsLEO PharmaNorth AmericaPharmaceuticalPicatoRegulation

Stellar Pharma to sell Apricus MycoVa in Canada


USA-based Apricus Biosciences (Nasdaq: ARI) has signed an exclusive license agreement with Canada’s…

Apricus BioscienceDermatologicalsLicensingMycoVaNorth AmericaPharmaceuticalStellar Pharmaceuticals

1 to 25 of 27 results

Back to top